Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1277-1283

  Wang, Qingfei ^a   Ding, Hui ^a   Liu, Baorui ^a   Li, Shau Hsuan ^b   Li, Ping ^b   Ge, Hailiang ^c   Zhang, Kui ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Akt inhibitor; Breast cancer; ErbB2 Neu; Mammary tumor; PTEN; Syngeneic

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, MOUSE; RIBONUCLEOSIDE; TRASTUZUMAB; TRICIRIBINE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MAMMARY NEOPLASMS, ANIMAL; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RIBONUCLEOSIDES;

EID: 84894497567     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2271     Document Type: Article

References (40)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Network CGA: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
3. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
4. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001. (Pubitemid 32878711)
5. Sotiriou C and Piccart MJ: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553, 2007. (Pubitemid 46985399)
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
7. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
8. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005. (Pubitemid 41464706)
9. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
10. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002. (Pubitemid 34111379)
11. Lan KH, Lu CH and Yu D: Mechanisms of trastuzumab resistance and their clinical implications. Ann NY Acad Sci 1059: 70-75, 2005. (Pubitemid 43211612)
12. Zhang S, Huang WC, Li P, et al: Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469, 2011.
13. Gajria D and Chandarlapaty S: HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11: 263-275, 2011.
14. Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280, 2006. (Pubitemid 43731112)
15. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402, 2007. (Pubitemid 47539306)
16. Di Cristofano A and Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 100: 387-390, 2000.
17. Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11: 289-301, 2011.
18. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177: 1647-1656, 2010.
19. Fujita T, Doihara H, Kawasaki K, et al: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94: 247-252, 2006. (Pubitemid 43151543)
20. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004. (Pubitemid 39485684)
21. Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol 28: 3366-3379, 2010.
22. Wang Q, Li SH, Wang H, et al: Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res 72: 4417-4428, 2012.
23. Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD and Muller WJ: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 97: 3444-3449, 2000. (Pubitemid 30183322)
24. Dourdin N, Schade B, Lesurf R, et al: Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68: 2122-2131, 2008. (Pubitemid 351521784)
25. Ursini-Siegel J, Rajput AB, Lu H, et al: Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor develop ment. Mol Cell Biol 27: 6361-6371, 2007. (Pubitemid 47435743)
26. Zhang H, Wang Q, Montone KT, et al: Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol 67: 15-25, 1999. (Pubitemid 29449450)
27. Frese KK and Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658, 2007. (Pubitemid 47327410)
28. Vargo-Gogola T and Rosen JM: Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7: 659-672, 2007. (Pubitemid 47327411)
29. Gopinathan A and Tuveson DA: The use of GEM models for experimental cancer therapeutics. Dis Model Mech 1: 83-86, 2008.
30. Schade B, Rao T, Dourdin N, et al: PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem 284: 19018-19026, 2009.
31. Mittelman A, Casper ES, Godwin TA, Cassidy C and Young CW: Phase I study of tricyclic nucleoside phosphate. Cancer Treat Rep 67: 159-162, 1983. (Pubitemid 13110649)
32. Hoffman K, Holmes FA, Fraschini G, et al: Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 37: 254-258, 1996.
33. Garrett CR, Coppola D, Wenham RM, et al: Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs 29: 1381-1389 2011.
34. Evangelisti C, Ricci F, Tazzari P, et al: Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 226: 822-831, 2011.
35. Lu CH, Wyszomierski SL, Tseng LM, et al: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13: 5883-5888, 2007. (Pubitemid 47583915)
36. Balasis ME, Forinash KD, Chen YA, et al: Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res 17: 2852-2862, 2011.
37. Dieterle A, Orth R, Daubrawa M, et al: The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer 125: 932-941, 2009.
38. Voskoglou-Nomikos T, Pater JL and Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-4239, 2003. (Pubitemid 37204044)
39. Park S, Jiang Z, Mortenson ED, et al: The therapeutic effect of anti-HER2neu antibody depends on both innate and adaptive immunity. Cancer Cell 18: 160-170, 2010.
40. Ferris RL, Jaffee EM and Ferrone S: Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28: 4390-4399, 2010.